Clinical trialObsUnknown
Using Digestive Microbial Information to Enhance the Early Detection of Pancreatic Cancer
SCREENING ORAL AND GUT MICROBES AS A MORE ACCURATE NON-INVASIVE TOOL FOR PANCREATIC CANCER EARLY DETECTION: A POPULATION-BASED CASE-CONTROL STUDY IN CHINA
- Outcome
- Outcome unknown
- Phase
- Obs
- Status
- Unknown
- Study type
- Observational
- Start
- 1 September 2020
- Expected end
- 30 December 2023
- Enrollment
- 100 participants
- Sites
- 1
- Primary outcomes
- microbial features by 16s rRNA sequencing
- Sponsor
- Other
- Results posted
- No
- Last update
- 18 January 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Pancreatic cancer (PCA) is a leading death-related cancer. There is an urgent need for accurate, noninvasive diagnostic options in the early detection of pancreatic cancer (PCA), since delayed diagnosis increases the risk of metastasis and recurrence. In this study, by analyzing gut and fecal microbial data among the pancreatic versus healthy populations, we aim to establish an early detection tool to improve PCA detection, and to explore potential diagnostic biomarkers.
Intervention public domain (ClinicalTrials.gov)
Other: Oral and Fecal Sample Collection. No interventions
Arm public domain (ClinicalTrials.gov)
PCA (): pancreatic cancer patients
Arm public domain (ClinicalTrials.gov)
NC (): normal control
Primary outcome public domain (ClinicalTrials.gov)
microbial features by 16s rRNA sequencing. Time frame: within 180 days.
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: PCA Newly diagnosed pancreatic cancer patients; No symptoms of jaundice; Did not yet receive any treatment NC Individuals who were undergoing routine screenings or physical examination Exclusion Criteria:
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 100 participants (actual).